Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134